World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 25 July 2023
Main ID:  ISRCTN69957414
Date of registration: 07/06/2018
Prospective Registration: No
Primary sponsor: Addiction Centre Stockholm (Beroendecentrum Stockholm)
Public title: Internet treatment of alcohol dependence in primary care
Scientific title: Internet-based Treatment of Alcohol Dependence in primary care - a randomised controlled trial
Date of first enrolment: 24/08/2017
Target sample size: 260
Recruitment status: Completed
URL:  https://www.isrctn.com/ISRCTN69957414
Study type:  Interventional
Study design:  Randomized controlled trial between-groups design (Treatment)  
Phase:  Not Applicable
Countries of recruitment
Sweden
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name: Sven    Andréasson
Address:  Riddargatan 1 Mottagningen för alkohol och hälsa 11435 Stockholm Sweden
Telephone: +46 (0)8 12345780
Email: sven.andreasson@ki.se
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Alcohol dependence according to ICD-10 criteria, hazardous alcohol consumption
2. Male and female, >18 years of age
3. Housing in Stockholm county

Exclusion criteria: 1. Severe mental illness
2. Severe dependence in need of specialist treatment
3. Abuse or dependence of other substances apart from alcohol and/or nicotine
4. Severe somatic illness
5. Non-Swedish speaking


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Alcohol dependence
Mental and Behavioural Disorders
Alcohol dependence
Intervention(s)
The participants will first do an application and read information about the study. After this the participants will provide their concent and answer a number of questionnaires. If inclusion criteria are fulfilled and exclusion criteria are checked, the study coordinator will contact the participant and do the randomization. All participants then provide a blood sample and are scheduled for an appointment to the GP. Participants are randomly allocated to one of two groups.

The Treatment as usual (TAU) receive care from the general practitioners provide treatmnt according to local routines and the training given on feedback on assessment questionairs and biomarkers in blood, offer mediciaton for treatment if applicable.

The iCBT groups receive of adaptation of motivational enhancement therapy and CBT, for two months added to TAU (treatment as usual). In the intervention arm iCBT is added to TAU and will run for two months. Participants are reminded to start work with a new task every week in iCBT.

The treatment duration depends on what the GP finds applicable and will probably differ in duration and in content. TAU is given in both study arms. Follow up in both study arms (as described before) are 3 and 12 months from baseline and involves providing blood samples and answering questionnaires.
Primary Outcome(s)
Change of weekly alcohol consumption and number of heavy drinking days measured by the Time line follow back instrument.
Secondary Outcome(s)
1. Change of degree of alcohol dependence ICD 10 criteria is measured using questionnaires at baseline, 3 and 12months
2. Change of consequences of drinking AUDIT scores is measured using questionnaires at baseline, 3 and 12 months
3. Change of symptoms of anxiety and depression HAD scores is measured using questionnaires at baseline, 3 and 12 months
4. Change of quality of life EQ5D is measured using questionnaires at baseline, 3 and 12 months
5. Change of levels of phosphatidylethanol (PEth) are measured using bloodsample at baseline, 3 and 12 months
6. Change of levels of aspartate aminotransferase (ASAT) are measured using bloodsample at baseline, 3 and 12 months
7. Change of levels of alanine aminotransferase (ALAT) are measured using bloodsample at baseline, 3 and 12 months
8. Change of levels of gamma-glutamyltransferase (GGT) are measured using bloodsample at baseline, 3 and 12 months
9. Patients’ satisfaction with treatment CSQ is measured using questionnaire at 3 months
Secondary ID(s)
N/A
Source(s) of Monetary Support
Forskningsrådet om Hälsa, Arbetsliv och Välfärd, Swedish Research Council Funding for Clinical Research in Medicine
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Old ethics approval format; Regional Ethics Review Board in Stockholm, 07/12/2016, 17/10/2017, ref: Dnr 2016/1367-31/2.
Results
Results available: Yes
Date Posted:
Date Completed: 31/03/2021
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history